Roy M Pollock

Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666.

Robert A Copeland, Nigel J Waters, Lei Jin, 2016, ACS medicinal chemistry letters.

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

Lars Bullinger, Andrew L Kung, Scott A Armstrong, 2011, Cancer cell.

Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor

Robert A Copeland, Nigel J Waters, Lei Jin, 2014, Biopharmaceutics & drug disposition.

Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.

Nigel J Waters, E. Olhava, N. Waters, 2015, Journal of controlled release : official journal of the Controlled Release Society.

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Robert A Copeland, Nigel J Waters, Lei Jin, 2015, Nature chemical biology.

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

Yonghong Xiao, Jen-Chieh Tseng, Robert A Copeland, 2011, Cancer cell.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Robert A Copeland, Nigel J Waters, E. Olhava, 2013, Blood.